Bristol Myers Squibb vs. Novo Nordisk: Which Healthcare Stock Is a Better Buy for 2027?

Source Motley_fool

Key Points

  • Bristol Myers Squibb maintains a powerful portfolio in oncology and hematology while trading at a low valuation multiple.

  • Novo Nordisk dominates the rapidly expanding markets for obesity and diabetes treatments with high net margins.

  • Which of these healthcare leaders belongs in your portfolio for 2027?

  • 10 stocks we like better than Bristol Myers Squibb ›

Investors often debate between established income producers and high-growth innovators. Choosing between Bristol Myers Squibb (NYSE:BMY) and Novo Nordisk A/S (NYSE:NVO) requires balancing deep value against the massive potential of weight-loss drugs.

Bristol Myers Squibb maintains a massive footprint in oncology and hematology, while Novo Nordisk has become a household name due to its dominance in the obesity and diabetes markets. Comparing these two reveals a classic trade-off between a diversified pharmaceutical giant and a specialized leader riding a generational healthcare trend.

The case for Bristol Myers Squibb

Bristol Myers Squibb discovers and delivers treatments for oncology, hematology, and neuroscience. Among pharmaceutical stocks, the company stands out for its extensive network of collaborations with partners like Johnson & Johnson (NYSE:JNJ), Zai Lab (NASDAQ:ZLAB), and Merck & Co. (NYSE:MRK). Most sales go through wholesalers and distributors, with its three largest U.S. wholesalers accounting for a substantial portion of global gross revenues. Customer concentration like this adds a layer of risk to the business, making these distribution relationships vital to its success.

In the 12 months ended Sept. 30, 2026, revenue reached about $50.0 billion, representing growth of roughly 4.2% over the previous year. Net income for this period was approximately $9.2 billion, which corresponds to a net margin of roughly 18.5%. This reflects a positive trend compared to the prior year, highlighting the company's ability to maintain high earnings while navigating a changing healthcare environment.

As of its December 2025 balance sheet, the debt-to-equity ratio is nearly 2.6x. This ratio compares total debt to shareholder equity, showing how much a company relies on borrowing to fund its operations. The current ratio is roughly 1.3x, which measures the ability to cover short-term liabilities with assets like cash or inventory. In the fiscal year ended Dec. 31, 2025, free cash flow was approximately $12.8 billion, providing significant capital for research and development.

The case for Novo Nordisk

Novo Nordisk A/S focuses on defeating serious chronic diseases, particularly obesity and diabetes, where it holds a dominant global position. The company also maintains leadership in rare blood and endocrine disorders, operating across the United States, Europe, and China. By focusing on high-demand chronic conditions, it has built a specialized business model that benefits from long-term patient needs. The company reaches a diverse global audience, though it does not disclose specific major customer concentrations in its standard filings.

In the 12 months ended Sept. 30, 2026, revenue reached about $49.0 billion. This represents revenue growth of approximately 5.7% compared to the prior year. Net income for the company was around $16.6 billion, resulting in a net margin of roughly 33.9%. This high level of profitability is supported by the significant demand for its blockbuster medications Ozempic and Wegovy.

As of its December 2025 balance sheet, the debt-to-equity ratio is roughly 0.7x, indicating a conservative approach to borrowing. The current ratio is nearly 0.8x, suggesting that its current assets are slightly insufficient to cover its short-term obligations. In the fiscal year ended Dec. 31, 2025, free cash flow reached approximately $4.3 billion. This cash generation allows the company to reinvest in manufacturing capacity to keep up with the global demand for its flagship products.

Risk profile comparison

Bristol Myers Squibb faces intense pricing pressure and reimbursement restrictions, particularly from the U.S. Inflation Reduction Act. This legislation has already led to government-set prices for Eliquis and Pomalyst, and upcoming negotiations for Orencia may further pressure top-line results. Furthermore, the company must manage the loss of market exclusivity for key products like Eliquis, Opdivo, and Revlimid, which could lead to rapid revenue declines as generic competitors enter the market.

Novo Nordisk A/S operates in a highly competitive market for obesity treatments, particularly against rivals like Eli Lilly & Co. (NYSE:LLY) and Pfizer Inc. (NYSE:PFE). Maintaining its leading market share requires constant manufacturing expansion to meet global demand for Wegovy and Ozempic. Additionally, the company must manage pricing pressures in the United States, where government and private payers often push for significant discounts on high-cost chronic medications.

Valuation comparison

Bristol Myers Squibb appears to be the more conservative value play, while Novo Nordisk carries a higher price tag reflecting its stronger net margin and growth potential.

MetricBristol Myers SquibbNovo Nordisk A/S
Forward P/E9.0x11.5x
P/S ratio2.4x3.5x

Valuation metrics include those sourced from Financial Modeling Prep (FMP) and may differ from those of other data providers.

The Forward P/E compares the current stock price to future earnings estimates over the next twelve months. Meanwhile, the P/S ratio measures market cap relative to sales over the past twelve months.

Which stock would I buy for 2027?

Novo Nordisk has the blockbuster drugs Wegovy and Ozempic (the same drug marketed for different purposes), but faces investor doubts about its market position given a deal with the federal government to lower prices for the GLP-1s, the emergence of generic competitors, and the apparent advances by Eli Lilly in developing weight loss drugs expected to be superior to Novo's offerings.

Still, the introduction of the once-a-day Wegovy pill in the U.S. has been a resounding success, and the business has a patent on injectable Ozempic/Wegovy till 2032, providing it some competitive moat. Still, Wall Street sees sales declining by about 3% in fiscal 2026, with net income contracting by 4% as pricing pressures slightly erode margins. Long-term, analysts expect the company to reverse the 2026 decline and resume growth as new products come online.

Bristol Myers Squibb, meanwhile, has made positive strides, with its newer growth brands gaining traction and some interesting candidates in the pipeline. The stock is cheap, and that seems to be for good reason. Investors have already priced in much of the upcoming difficulty, which softens the downside.

Revenue for the current fiscal year should edge up 3% to $49.8 billion, with a much healthier rise in net income of more than 40% to $11.2 billion.

Bristol Myers has attractively low forward price-to-earnings and price-to-sales ratios compared to the slightly pricier Novo Nordisk. Both stocks, however, are priced in value stock territory. The decision here is one not to overthink: Bristol Myers Squibb is growing revenue and net income this year while Novo Nordisk's are shrinking. For 2027, go with BMY.

Should you buy stock in Bristol Myers Squibb right now?

Before you buy stock in Bristol Myers Squibb, consider this:

The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Bristol Myers Squibb wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.

Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $305,941!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $771,325!*

Now, it’s worth noting Stock Advisor’s total average return is 719% — a market-crushing outperformance compared to 192% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.

See the 10 stocks »

*Stock Advisor returns as of November 22, 2026.

Brendan Coffey has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Bristol Myers Squibb, Eli Lilly, Merck, Novo Nordisk, and Pfizer. The Motley Fool recommends Johnson & Johnson. The Motley Fool has a disclosure policy.

Disclaimer: For information purposes only. Past performance is not indicative of future results.
placeholder
Gold Price Today: Can XAU/USD Hold $3,500? | Mitrade AUGold approaches US$3,500 as Fed tightening fears drive sharp weekly losses. Explore XAU/USD levels, Treasury yields and the outlook for Australian traders.
Author  Mitrade Team
Nov 20, Fri
Gold approaches US$3,500 as Fed tightening fears drive sharp weekly losses. Explore XAU/USD levels, Treasury yields and the outlook for Australian traders.
placeholder
Australia’s jobs market just cracked — has the AUD/USD rate story flipped?Australia’s weakening jobs market is raising fresh questions about the RBA’s interest rate outlook and the Australian dollar. Explore why AUD/USD could be losing support, the key factors driving currency movements and what Australian forex traders should watch next.
Author  Mark Garro
Nov 20, Fri
Australia’s weakening jobs market is raising fresh questions about the RBA’s interest rate outlook and the Australian dollar. Explore why AUD/USD could be losing support, the key factors driving currency movements and what Australian forex traders should watch next.
placeholder
Market News Today Australia: VIX Surges Nearly 16%, Gold Breaks US$3,600 and US Stocks SlideVIX jumps 15.8%, Nasdaq 100 falls 2.21% and gold slips below US$3,600. Explore Anthropic’s debut and the outlook for Australian CFD traders.
Author  Mitrade Team
Nov 20, Fri
VIX jumps 15.8%, Nasdaq 100 falls 2.21% and gold slips below US$3,600. Explore Anthropic’s debut and the outlook for Australian CFD traders.
placeholder
Is Tech in a Bear Market? 20 Tech Stocks Fall Up to 76% From HighsAll 20 tech stocks on a list from financial newsletter The Kobeissi Letter trade at least 25% below record highs. CoreWeave (CRWV) leads the slide at 76%.Additionally, the S&P 500 has lost over $6 tri
Author  Beincrypto
Nov 20, Fri
All 20 tech stocks on a list from financial newsletter The Kobeissi Letter trade at least 25% below record highs. CoreWeave (CRWV) leads the slide at 76%.Additionally, the S&P 500 has lost over $6 tri
placeholder
Gold and Bitcoin Are Falling. Peter Schiff Sees Opportunities for BothPeter Schiff says gold should not have fallen at all, while Bitcoin (BTC) has not fallen enough. The gold advocate calls the metal’s drop a buying opportunity and Bitcoin’s a selling opportunity.Both
Author  Beincrypto
Nov 20, Fri
Peter Schiff says gold should not have fallen at all, while Bitcoin (BTC) has not fallen enough. The gold advocate calls the metal’s drop a buying opportunity and Bitcoin’s a selling opportunity.Both
goTop
quote